Therapeutic Advances in Rare Disease

该期刊采用CRediT贡献者角色分类法,包含14种角色,用于描述每位作者对工作的具体贡献;作者需在提交过程中列出每位作者的贡献,并在提交稿件的致谢部分之后加入作者贡献标题。 模型中文摘要

As part of our commitment to ensuring an ethical, transparent and fair peer review and publication process, this journal has adopted CRediT (Contributor Roles Taxonomy). CRediT is a high-level taxonomy, including 14 roles, which is used to describe each author’s individual contributions to the work. You will be asked to list the contribution of each author as part of the submission process. Please…

该期刊鼓励作者在符合伦理和法律要求的前提下,将研究数据共享到相关公共数据仓库,在数据可用性声明中链接数据,若无法共享数据则说明原因,并在研究中引用该数据。 模型中文摘要

The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…

涉及人类参与者、人类数据或人类组织的研究论文必须声明相关伦理委员会或机构审查委员会批准了研究或豁免了批准要求,并提供审查委员会的完整名称、所属机构及批准编号;若无需伦理批准,须明确声明。 模型中文摘要

Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…

该期刊为开放获取同行评审期刊,接受的文章在出版后立即免费在线发布,采用知识共享许可;文章处理费为2250美元,在同行评审后稿件被接受时、出版前支付,可能需缴税。 模型中文摘要

Therapeutic Advances in Rare Disease is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. The article processing charge (APC) is $2,250 USD. More details on APCs for specific article types can be found in the Article Type section below. The arti…

该期刊采用单匿名同行评审,审稿人姓名始终对投稿作者保密;稿件先经初步评估,不符合要求会被退回修改,超出范围或不合适的稿件可能未经同行评审即被拒稿。 模型中文摘要

The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…

期刊和Sage非常重视版权侵权、抄袭或其他违反出版最佳实践的问题,作者应阅读Sage完整的抄袭政策以及期刊可能采取的措施。 模型中文摘要

The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.

该期刊接受已在预印本服务器发布的稿件,提交时需在指定字段填写预印本DOI,并建议在提交时告知编辑部;同行评审期间不应在预印本服务器发布更新版本。 模型中文摘要

The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…

根据ICMJE要求,临床试验须在首个参与者入组时或之前在WHO认可的公共试验注册机构注册,作为考虑发表的先决条件;试验注册机构名称、URL和注册编号必须包含在摘要末尾。 模型中文摘要

The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.